


CLAIMS

- 1) A pharmaceutically acceptable salt of a compound according to Formula (I):



wherein the salt is an hydrochloric acid, or a maleic acid salt.

- 2) A pharmaceutically acceptable salt according to claim 1, wherein the salt is a 1:1 free base/hydrochloric acid salt.
- 3) A pharmaceutically acceptable salt according to claim 1, wherein the salt is a 1:1 free base/maleic acid salt.
- 4) A pharmaceutically acceptable salt according to claim 1, wherein the salt is in a crystalline form.
- 5) A pharmaceutically acceptable salt according to any one of claim 1-2, wherein the salt is a pharmaceutically acceptable solvate of the salt.
- 6) A pharmaceutically acceptable salt according to any one of claim 1-2, wherein the salt is a hydrate of the salt.
- 7) A pharmaceutically acceptable salt according to claim 6, wherein the hydrate of the salt is a 1:1:3 Free Base/HCl/H₂O adduct.
- 8) A pharmaceutically acceptable salt or pharmaceutically acceptable hydrate of a salt according to claims 7, wherein the hydrate of the salt is in a crystalline form.
- 9) A pharmaceutically acceptable hydrate of a salt according to claim 8, wherein the 1:1:3 Free Base/HCl/H₂O hydrate of the salt is characterized at least by a powder X-ray diffraction peak at any one or more of the following positions: 7.25, 8.31, 8.78, 10.69, 11.96, 12.25, 13.17, 13.74, 16.23, 16.71, 19.26, 19.64, 20.15, 20.57, 20.95, 21.38, 21.69, 22.77, 23.37, 25.14, 25.71, 25.89, 27.66, 28.57, 28.81, 29.17, 29.58, 30.63, 30.94, 32.06, 32.63, 34.14, 36.22, 36.67, and 37.12° 2θ ± 0.2° 2θ.
- 10) A pharmaceutically acceptable hydrate of a salt according to claim 8, wherein the 1:1:3 Free Base/HCl/H₂O hydrate of the salt characterized by the following diffraction parameters:

Molecular formula	C ₂₁ H ₂₄ N ₅ O ₃ S.Cl ₃ (H ₂ O)				
Molecular weight	516.02				
Crystal system	Monoclinic				
Space group	P2 _{1/n}	a	13.1388(4) Å	α	102.089(2)°
		b	8.9437(3) Å	β	
		c	21.6376(9) Å	γ	
V	2486.24(15) Å ³				
Z	4				

Dc	1.379 mg / m ³
μ	0.284 mm ⁻¹
Source	Mo-K α , 0.71073 Å
F(000)	1088
T	120(2) K
Crystal	colourless prism, 0.39 x 0.16 x 0.12 mm
θ range for data collection	2.982 – 27.483°
Completeness	99.3%
Reflections	21028
Unique reflections	5649
R _{int}	0.0307

- 11) A pharmaceutical composition comprising a pharmaceutically acceptable hydrate of a salt according to any one of claims 1-10, and a pharmaceutically acceptable carrier, excipient or diluent.
- 12) A pharmaceutical composition according to claim 11, comprising a further therapeutic agent.
- 13) A pharmaceutically acceptable salt according to any one of claims 1-10, or a pharmaceutical composition according to 11 or 12 for use in medicine.
- 14) A pharmaceutically acceptable salt according to any one of claims 1-10, or a pharmaceutical composition according to 11 or 12 for use in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
- 15) The use according to claim 13 or 14, wherein the pharmaceutically acceptable salt according to any one of claims 1-10, or the pharmaceutical composition according to 11 or 12 is to be administered in combination with another therapeutic agent.
- 16) The pharmaceutical composition according to claim 12, or the use according to claim 15, wherein the further therapeutic agent is an agent for the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
- 17) A method for preparing a [Compound according to Formula I:HCl:3H₂O] adduct in a solid crystalline form comprising the steps of:
 - i) mixing the compound of Formula I suspended in DCM, with MeOH at 35°C,
 - ii) adding water under stirring at 35°C for at least 15 min,
 - iii) separating the organic layer,
 - iv) adding a 10% w/w solution of HCl in MeOH to the organic layer obtained in the previous step iii),
 - v) separating the resulting solid by filtration obtained in the previous step iv),
 - vi) drying said resulting solid obtained in the previous step v),
 - vii) adding the solid obtained in the previous step vi) to a 1.6/0.4 formic acid/water solution, under stirring at 55°C

- viii) adding water to the solution obtained in the previous step vii),
 - ix) separating by filtration the resulting solid obtained in the previous step viii), and
 - x) drying the resulting solid obtained in the previous step ix).
- 18) A method for preparing a maleic acid salt of a compound according to Formula I according to claims 1 by combining the compound according to Formula I with maleic acid, in an inert solvent and precipitating said salt from said solvent.
 - 19) A method for preparing a maleic acid salt of a Compound according to Formula I according to claims 1 by combining Compound 1 and a salt forming agent in a suitable solvent in order to achieve full dissolution, followed by a controlled solvent evaporation in order to achieve supersaturation, and thus crystallization of the corresponding salt.
 - 20) The method according to claim 18 or 19, wherein the salt is obtained by mixing Compound 1, and the acid in a molar ratio of between 2:1 and 1:2 of Compound 1:acid.
 - 21) The method according to claim 18 or 19, wherein the solvent is selected from acetonitrile, dioxane, THF, acetone, DCM, and MeOH.
 - 22) A process for the preparation of the maleic acid salt of a compound according to Formula I according to claims 3 comprising the following steps:
 - i) suspending 1 equivalent of the compound of Formula I in 20 volumes of 5 % water in acetone at 25°C,
 - ii) warming the suspension of step i) to 50°C,
 - iii) adding 2.1 equivalent of maleic acid (1 M solution in THF) to the stirred suspension at 50°C obtained in the previous step ii),
 - iv) cooling the mixture of step iii) to 25°C at 1°C/min and stirring at 25°C for 22 h,
 - v) separating by filtration the resulting solid obtained in the previous step iv),
 - vi) drying under suction said resulting solid obtained in the previous step v).